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Except for conversion to bile salts, there is no major
cholesterol degradation pathway in mammals. Effi-
cient excretion from the body is therefore a crucial
element in cholesterol homeostasis. Yet, the exis-
tence and importance of cholesterol degradation
pathways in humans is a matter of debate. We quan-
tified cholesterol fluxes in 15 male volunteers using
a cholesterol balance approach. Ten participants
repeated the protocol after 4 weeks of treatment
with ezetimibe, an inhibitor of intestinal and biliary
cholesterol absorption. Under basal conditions,
about 65% of daily fecal neutral sterol excretion
was bile derived, with the remainder being contrib-
uted by direct transintestinal cholesterol excretion
(TICE). Surprisingly, ezetimibe induced a 4-fold
increase in cholesterol elimination via TICE. Mouse
studies revealed that most of ezetimibe-induced
TICE flux is mediated by the cholesterol transporter
Abcg5/Abcg8. In conclusion, TICE is active in hu-
mans and may serve as a novel target to stimulate
cholesterol elimination in patients at risk for cardio-
vascular disease.
INTRODUCTION
The reverse cholesterol transport (RCT) pathway is a crucial anti-
atherogenic mechanism which mediates the removal of choles-
terol from body tissues into feces (Glomset, 1968). The mecha-
nism by which cholesterol is taken up from peripheral cells,
including macrophages, has been subject to intense research
over the last few decades. It is now generally thought that the
ABC transporters ABCA1 (ATP binding cassette subfamily ACell Metmember 1) and ABCG1 primarily regulate cholesterol efflux
from cells, though in the absence of these transporters compen-
satory pathways may operate. After uptake of the free choles-
terol by plasma lipoproteins, the paradigm is that cholesterol is
secreted into the intestinal lumen after passage via the hepato-
biliary pathway. However, several groups have now demon-
strated that direct transintestinal excretion of plasma-derived
cholesterol may contribute to RCT (Kruit et al., 2005; van der
Velde et al., 2007; Temel et al., 2010; Le May et al., 2013). In
mice, this transintestinal cholesterol excretion (TICE) route was
shown to account for 30% of total fecal neutral sterol (FNS)
excretion under basal conditions and was enhanced by Liver-
X-receptor-activated and peroxisome-proliferator-activated re-
ceptor-delta (PPAR-d) agonists (van der Veen et al., 2009; van
der Velde et al., 2007; Vrins et al., 2009).
The contribution of TICE to FNS excretion in humans remains,
however, to be established. Le May et al. (2013) published the
first direct evidence for the activity of the pathway in explants
from human small intestine mounted in Ussing chambers. The
presence of TICE in humans would offer a plausible explanation
for observations reported in early literature. In patients with com-
plete biliary obstruction, a substantial portion of fecal sterols was
found to be of nondietary origin (Stanley et al., 1959), and in bile-
diverted patients, the intestinal mucosa was found to secrete
250–400 mg of cholesterol per day (Cheng and Stanley, 1959).
A human intestinal perfusion study suggested the existence of
TICE in humans, with the presence of a substantial flux of choles-
terol from enterocytes directly in the intestinal lumen (Simmonds
et al., 1967). These and a number of other early reports (Deckel-
baum et al., 1977; Hellman et al., 1955; Rosenfeld and Hellman,
1959) were highly criticized, predominantly due to the small num-
ber of observations and the study limitations of bile-diverted
conditions, including compromised cholesterol absorption and
strongly upregulated cholesterol and bile salt synthesis. These
studies may have been disregarded due to limitations of intesti-
nal perfusion studies, such as the absence of food; biliary and
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segments; and the specific composition of the perfusate, which
may have influenced the excretory capacity of enterocytes.
Although these experiments collectively lend support to the ex-
istence of TICE in humans, assessment of TICE’s importance
relative to the biliary pathway has remained elusive. This is
largely caused by the technical challenges faced in the attempt
to reliably estimate this flux in humans, which requires simulta-
neous assessment of cholesterol absorption, biliary secretion,
and—as a final common pathway—FNS excretion. By
combining previous experience from validated models in mice
(van der Veen et al., 2009) and humans (Harchaoui et al., 2009;
Jakulj et al., 2013; Stellaard et al., 1984), we set out to quantify
body cholesterol fluxes in a group of mildly hypercholesterol-
emic, healthy, male subjects using a combined stable isotope
method with differentially labeled cholesterol molecules and
bile salt tracers. To evaluate the dynamic behavior of the various
fluxes, the protocol was later repeated in a subgroup of the par-
ticipants following treatment with ezetimibe. In this series of ex-
periments, we confirm that hepatobiliary secretion is the major
cholesterol export pathway in humans under basal conditions.
We also provide in vivo evidence for the activity of TICE in hu-
mans and, importantly, show that this cholesterol excretion
pathway accounts for most of the cholesterol-mobilizing effect
induced by ezetimibe. Studies in mice confirmed these results
and suggested that most of the ezetimibe-induced TICE




Fifteen out of 20 screened subjects met the inclusion and exclu-
sion criteria detailed in the Experimental Procedures section. All
completed the first experiment focusing on baseline cholesterol
fluxes. Ten out of 15 participants consented to participate in the
second experiment after a 28-day treatment period with 10 mg
ezetimibe daily (until day 0 of the study schedule displayed in
Figure 1A). Five subjects dropped out in the second study
because the experiment was fairly intense and time consuming.
The second experiment started 6.3 ± 0.9 months after comple-
tion of the basal experiment. Baseline characteristics of the 15
initial participants and the ten who completed both study periods
at the start of each experiment are shown in Table 1. There was
no difference between the first and the second group in any of
the parameters measured.
Cholesterol Kinetic and Bile Salt Parameters under
Basal Conditions
We then set out to investigate the kinetics of cholesterol disposal
from the body. Figures 1B and 1C display average curves of
fractional enrichments in plasma and feces of intravenously
administered 13C2-cholesterol. Between days 3 and 5, the tracer
enrichments of plasma and feces became identical. Appar-
ently, no de-novo-synthesized cholesterol in the intestine was
directly shed into the intestinal lumen. The minor contribution
of unabsorbed dietary cholesterol did not seem to influence fecal
enrichment. With respect to the intravenously administered
13C2-cholesterol tracer, the fast initial phase of decrease in tracer
enrichment is due to the interplay of tracer equilibration in the784 Cell Metabolism 24, 783–794, December 13, 2016fast miscible cholesterol pool as well as efflux of unlabeled
cholesterol from the periphery (Figures 1B and 1C). The initial la-
bel enrichment after intravenous infusion is somewhat higher in
the case of ezetimibe-treated subjects (Figure 1C) due to the
lower plasma cholesterol levels. The kinetics of the orally admin-
istered D7-cholesterol tracer was somewhat delayed due to
intestinal absorption and chylomicron transport via the lymph.
After uptake of the chylomicron remnants, the cholesterol is
redistributed by the liver in very low density lipoprotein (VLDL),
which is transformed to low-density lipoprotein (LDL) in the cir-
culation, and the bulk of the LDL cholesterol then cycles back
to the liver. The gradual decay in enrichment after the equilibra-
tion phase is mainly caused by activity of the RCT pathway. As
expected, there was no difference in kinetics in this phase
(days 4–7.5) when comparing the decay of orally versus intrave-
nously administered cholesterol tracers (p = 0.3). Clearly, uptake
of D7-cholesterol is much lower in ezetimibe-treated subjects
(Figure 1C).
To distinguish RCT via the biliary pathway or TICE, we deter-
mined biliary cholesterol secretion. Since direct cannulation of
the bile duct in humans is impossible for ethical reasons, we
developed an indirect method. Biliary cholesterol secretion is
known to be driven by hepatobiliary bile salt secretion under
physiological conditions, resulting in a quasilinear relationship
between the two parameters (Carey and Mazer, 1984). Because
of this direct coupling, measurement of bile salt kinetics and the
cholesterol:bile salt ratio in bile can be used to calculate biliary
cholesterol secretion, provided that the ratio is similar in different
patients. We determined cholate kinetics in the volunteers using
a deuterium-labeled cholate tracer technique, as previously
described in Stellaard et al. (1984). Cholate pool sizes and the
fractional elimination rate of total bile salt from blood (kBS) are
shown in Table S1. The cholesterol:cholate ratio for each partic-
ipant was determined by eluting bile absorbed by an Enterotest
at T = 24 hr (Supplemental Experimental Procedures). Figures 2A
and 2B show the relation between the cholesterol and cholate,
as well as the chenodeoxycholate concentration eluted from
the Enterotests, with regression lines shown for basal and ezeti-
mibe conditions. In Figure 2A, the slope of the line under the
basal condition seems somewhat steeper, though not statisti-
cally different from the ezetimibe-treated group (p = 0.49). We
therefore chose to combine the data for the basal and ezetimibe
conditions, and linear fitting of these data in Figure 2A (r2 = 0.8,
p < 0.001) yielded a cholesterol/cholate ratio of 0.23 ± 0.03.
Data points for chenodeoxycholate were very similar, and
regression lines for basal and ezetimibe conditions fully overlap-
ped. We validated the use of the Enterotest as a measure of the
cholesterol:bile salt ratio in a separate experiment carried out in
five healthy male volunteers. We harvested duodenal bile both
endoscopically and via the Enterotest and showed that the cho-
lesterol:cholate ratios obtained using both methods were com-
parable (Supplemental Experimental Procedures; Figure S1).
Mean biliary cholesterol secretion was calculated to be 783 ±
69 mg/day under basal conditions in 15 participants.
Cholesterol Fluxes and Sources of FNS under Basal
Conditions
Using the calculated biliary cholesterol secretion rates, we
analyzed the contribution of the various cholesterol fluxes to
A
B C
Figure 1. Scheme of Experiment, A, and Combined Plasma and Feces 13C2 and D7 Cholesterol Enrichment Curves, B and C
(A) The abbreviation ‘‘t.i.d.’’ indicates three times a day.
(B) Plasma excursions are depicted for intravenously and orally administered stably labeled 13C2- and D7-cholesterol, respectively, as well as fecal appearance of
13C2-cholesterol under basal conditions.
(C) Plasma excursions are depicted for intravenously and orally administered stably labeled 13C2- andD7- cholesterol, respectively, as well as fecal appearance of
13C2-cholesterol after 4 weeks of treatment with ezetimibe.FNS excretion. The fluxes were corrected for cholesterol (re)ab-
sorption, with intestinal fractional cholesterol absorption corre-
sponding to the difference between oral and intravenous decay
kinetics, as described by Zilversmit (1983). Under basal condi-
tions, cholesterol absorption contributed to 24% ± 11%. Of the
daily excreted FNS, 97 ± 6 mg was derived from the diet,and
biliary cholesterol secretion accounted for 601 ± 63 mg/day.
TICE contributed 197 ± 38 mg/day to FNS.
Ezetimibe-Induced Changes in Cholesterol Fluxes and
Sources of FNS
Because of the time elapsed between the first and second ex-
periments, we stopped administration of ezetimibe at the onset
of the second experiment to monitor return of the FNS to base-
line levels. As shown in Figure 3A, ezetimibe increased FNSabout 2-fold, and, after day 3, the amount of FNS gradually
decreased to return almost back to baseline levels at day 9.
Cumulative FNS excretion was linear up to day 4, and the slope
decreased thereafter (Figure 3B). Fecal bile salt excretion
increased about 50%with ezetimibe treatment, but this increase
did not return to baseline (Figure 3C), resulting in a linear increase
in the total amount of fecal bile salts excreted during the course
of the experiment (Figure 3D).
Ezetimibe significantly reduced plasma total cholesterol (TC)
and LDL cholesterol (LDL-C) by 17.3% ± 8.0% and 25.4% ±
8.1%, respectively (Table 1). Plasma high-density lipoprotein
cholesterol (HDL-C) and triglyceride (TG) levels were not signifi-
cantly affected (Table 1). Equivalent to the basal experiment,
cholesterol fluxes were measured and calculated from the frac-
tional enrichment of intravenously administered 13C2-cholesterolCell Metabolism 24, 783–794, December 13, 2016 785
Table 1. Baseline Characteristics
Experiment Basal Basal Ezetimibe
Male subjects, n 15 10 10
Age, years 62.1 ± 2.9 62.7 ± 2.9 62.7 ± 2.9
Smoking, n 4 2 2
BMI, kg/m2 25.7 ± 0.6 25.8 ± 0.7 25.6 ± 0.7
SBP, mmHg 142 ± 3 140 ± 3 143 ± 5
DBP, mmHg 85 ± 2 84 ± 2 89 ± 3
Total cholesterol,
mmol/L
5.59 ± 0.17 5.62 ± 0.19 4.74 ± 0.12*
LDL cholesterol,
mmol/L
3.74 ± 0.13 3.81 ± 0.13 2.87 ± 0.08*
HDL cholesterol,
mmol/L
1.32 ± 0.07 1.38 ± 0.07 1.41 ± 0.08
Triglycerides,
mmol/L






Glucose, mmol/L 5.6 ± 0.1 5.5 ± 0.2 5.5 ± 0.1
Data are presented as means ± SEM. *p % 0.05; as compared to basal
conditions (n = 10). As triglyceride data were skewed, data were log-
transformed prior to testing; untransformed medians and range are
presented.and orally administered D7-cholesterol in plasma during the first
3 days, when the ezetimibe effect on sterol excretion was still
optimal (Figure 3A). Note that bile was sampled at t = 24 hr. There
was no significant difference between the basal data of these ten
subjects compared to the original cohort of 15 (data not shown).
Ezetimibe did not affect biliary bile salt content or the biliary cho-
lesterol:cholate ratio (Figure 2). Bile salt pool size and fractional
turnover rate were also not significantly affected by ezetimibe
(Supplemental Experimental Procedures). However, ezetimibe
increased fecal bile salt excretion from 205 ± 27 to 332 ±
40 mg/day (Figure 4E). Ezetimibe had no significant effect on
either dietary cholesterol intake (Figure 4A) or biliary cholesterol
secretion, which was calculated to be 769 ± 106 mg/day, and
thereby did not deviate from baseline in these subjects (Fig-
ure 4B). Ezetimibe reduced intestinal fractional cholesterol
absorption by 59% (Figure 4C) and increased FNS from
935 ± 80 to 1,834 ± 84 mg/day (Figure 4D). TC synthesis (bile
saltsfeces + FNS  CHdiet) increased by 2-fold to a total of
1,950 ± 154 mg/day (Figure 4F, p = 0.001). The ezetimibe-
induced increase in FNS output was comparable to that seen
in previous reports (Lin et al., 2011; Sudhop et al., 2002, 2009).
Because ezetimibe selectively inhibits NPC1L1, the increase in
FNS loss has always been attributed to inhibition of cholesterol
absorption. We now show that the increase in FNS output is
mainly caused by a 4-fold increase in TICE (from 252 ± 46 mg/
day to 1,024 ± 114 mg/day, p = 0.001, Figure 4G). Figure S2
depicts the effect of ezetimibe on FNS and TICE in individual
subjects. As expected, ezetimibe increased FNS excretion in
all subjects, although the response was quite variable. A similar
response was observed for TICE rate.
Interestingly, and contrary to our expectation, there was no
correlation between the effect of ezetimibe on FNS and the per-
centage of absorption (data not shown). The target of ezetimibe,
NPC1L1, is expressed in the human liver, albeit much less than in
the intestine (Zúñiga et al., 2008), and genomic variants have786 Cell Metabolism 24, 783–794, December 13, 2016been associated with increased risk of gallstone disease (Laurid-
sen et al., 2015). Therefore, ezetimibe could influence biliary
cholesterol secretion. However, in accordance with our data,
Wang et al. (2008) and recently Kishikawa et al. (2015) found
no effect of ezetimibe on the molar ratio of cholesterol:bile salts
in bile, indicating that the role of NPC1L1 in gallstone disease
may be more complex.
Whole-Body Sterol Efflux Strongly Correlates with TICE
Given the low dietary cholesterol intake recorded in this study,
most of the sterols excreted in the feces must be derived from
de novo synthesis. Cholesterol synthesis in humans comes
mainly from extrahepatic sources; the hepatic contribution has
been estimated to be around 10% (Dietschy and Turley, 2002).
Consequently, most of the FNS originated in the periphery. Fig-
ure S3 shows the values for FNS as a function of either biliary
cholesterol secretion (Figure S3A) or TICE (Figure S3B) for the
ten individual subjects who completed the whole study. FNS
output correlated poorly with biliary cholesterol secretion but
quite well with TICE, primarily in the condition with ezetimibe.
Under basal conditions, TICE is probably not prominent enough
to correlate significantly with FNS.
Studies inMice on theMechanism of Ezetimibe-Induced
TICE
We then set out to investigate the mechanism by which ezeti-
mibe induces TICE. C57BL/6J mice were fed a diet with or
without 0.005% ezetimibe for 2 weeks. Similar to the procedure
in the human study, cholesterol fluxes were determined using
stable-isotope-labeled cholesterol tracers.
Similar to our findings in humans, ezetimibe did not affect di-
etary intake (Figure 5A), though it slightly increased biliary
cholesterol secretion (Figure 5B). As expected, cholesterol ab-
sorption was strongly inhibited (Figure 5C), and FNS output
was enhanced (7.3 ± 0.3 versus 1.9 ± 0.1 mg/day, Figure 5D)
In contrast to the human experiment, fecal bile salt excretion
was not affected (Figure 5E), yet total sterol synthesis strongly
increased (Figure 5F). Biliary cholesterol secretion increased
from 0.8 ± 0.04 to 1.0 ± 0.06 mg/day with ezetimibe treatment.
However, this was by far not enough to account for the
5.4 mg/day increase in FNS. Since dietary intake was 1.1 ±
0.05 versus 0.9 ± 0.05 mg/day and cholesterol absorption was
almost completely blocked, the amount of FNS that could be
attributed to dietary intake and biliary output was about 2 mg/
day. Consequently, the remaining 5.3 mg/day of FNS was due
to TICE (Figure 5G), plus perhaps a small amount of cholesterol
derived from shed enterocytes which we, in a previous study,
estimated to be about 15% (i.e., 0.3 mg/day) under baseline
conditions (van der Velde et al., 2007). To ascertain whether
the increased flux through the enterocytes could be linked
back to increased expression of genes, we performed microar-
ray expression analysis. Except for Stard4, which has been
implicated in intracellular cholesterol transport (Iaea et al.,
2015), no other known gene potentially linked to cellular choles-
terol transport or secretion was upregulated in the small intes-
tine. KEGG pathway analysis demonstrated upregulation of
pathways involved in xenobiotic metabolism and a slight upregu-
lation of genes involved in cholesterol synthesis (data not
shown). Surprisingly, expression of the cholesterol heterodimer
Figure 2. Relation between Cholesterol and Cholate or Chenodeoxycholate Eluted from Enterotest
The cholesterol, cholate, and chenodeoxycholate content in bile from ten volunteers was determined by eluting bile absorbed by an Enterotest at T = 24 hr before
(B) and after (C) 4 weeks of treatment with ezetimibe.Abcg5/Abcg8 was downregulated and confirmed by QPCR
(39%, p < 0.01; and 44%, p < 0.01, respectively). Since we
have shown in an earlier study that Abcg5/Abcg8 may be a key
mediator of TICE, we investigated the role of this heterodimer
in ezetimibe-induced TICE flux in Abcg8-deficient mice, which
phenocopy Abcg5/g8 double knockout mice. In the absence of
Abcg8, dietary cholesterol intake did not change (Figure 5A),
and biliary cholesterol secretion decreased but was still slightly
stimulated by ezetimibe (Figure 5B). Cholesterol absorption
was lower in Abcg8/ mice and strongly inhibited by ezetimibe
(Figure 5C). In the absence of Abcg8, ezetimibe had a much
smaller effect on FNS (Figure 5D). In contrast to our human
study, ezetimibe did not impact fecal bile acid secretion (Fig-
ure 5E). Ezetimibe increased total sterol synthesis (Figure 5F),
but the effect was much less pronounced compared to wild-
type (WT) mice. The decreased impact of ezetimibe on TC syn-
thesis was due to a decrease in TICE (Figure 5G), which dropped
from 5.4 ± 0.3 mg/day in WT to 2.0 ± 0.4 mg/day in the ezetimibe
condition, indicating that most of the TICE flux is mediated by
Abcg5/g8. Similar to the findings in the human study, there
was no correlation between biliary cholesterol secretion and
FNS in either WT or Abcg8/ mice (Figures S3C and S3E).
However, FNS correlated highly with TICE both in WT and in
Abcg8/ mice (Figures S3D and S3F). Most of the effect of eze-
timibe on FNS excretion could be accounted for by an increase in
TICE in mice. The effect was, however, more pronounced in
mice, probably because the inhibition of NPC1L1 was stronger.
Disruption of gene expression of the heterodimer Abcg5/g8
decreased the effect of ezetimibe on FNS by about 50%. Since
ezetimibe is selective for NPC1L1, there must be an interaction
between this protein and Abcg5/g8—probably at the level of
the brush border membrane. The ABCG5/G8 transporter and
NPC1L1 are coexpressed in the small intestine in both humans
and mice (Masson et al., 2010). Because these two transporters
have opposing functions, continuous cycling of cholesterol at
the apical membrane apparently occurs, generating a highly
sensitive mechanism to control cholesterol levels in enterocytes.
The net fluxes under the different conditions, as obtained in the
current study, are given in the simplified scheme of cholesterol
transport depicted in Figure 6. Assuming that the inhibition in
fluxes measured in the Abcg8/ mice can be translated directlyto the WT controls, we have calculated the flux distribution in
absence and presence of ezetimibe. Net influx via NPC1L1 in
the absence of ezetimibe is calculated from the dietary intake,
biliary cholesterol secretion, and absorption. Net efflux = TICE
can be calculated from the stable isotope enrichments, as ex-
plained in the Supplemental Experimental Procedures, or can
simply be calculated from fecal excretion minus biliary secretion
and dietary intake, corrected for absorption. The data show that,
in both WT and Abcg8 KO mice, ezetimibe mobilizes cholesterol
from the basolateral side of the enterocyte, although we cannot
exclude that some of the cholesterol may be synthesized in
the enterocyte. The effect is 3-fold higher in WT compared to
Abcg8/ mice.
We speculate that inhibition of NPC1L1 will lead to a higher
cholesterol content of the apical membrane of the enterocytes,
inducing increased activity of Abcg5/g8; this is in line with a
recent study by Nakano et al. (Nakano et al., 2016). Note that
ezetimibe increased TICE also in Abcg8/ mice, indicating
that the heterodimer is not the only transporter involved in
cholesterol secretion by the enterocytes. Activity of Abcb1a
and Abcb1b may be responsible for this phenomenon (Le May
et al., 2013). However, we also cannot exclude that ezetimibe
induces some cell shedding. In mice, ezetimibe treatment did
not affect bile salt excretion, though in humans, we observed
significantly increased fecal bile salt output. This is in line
with observations in healthy individuals who were sequentially
treated with ezetimibe and ezetimibe combined with plant ste-
rols for 3 weeks each as compared to placebo (Lin et al.,
2011). Furthermore, a trend toward an increase in fecal BA
loss was found in males treated with ezetimibe for 2 weeks
(p = 0.068) (Sudhop et al., 2002). Recently, ezetimibe was shown
to alter the composition of the microbiota (Catry et al., 2015;
Zhong et al., 2015). Although the effect of changes in microbiota
on bile salt composition was not reported in these studies, it
seems reasonable to speculate that alterations in microbiota
composition contributed to the changes in bile salt excretion
observed in the present study.
Study Limitations
An important step in quantification of TICE in humans in our study
is the determination of biliary cholesterol secretion. For ethicalCell Metabolism 24, 783–794, December 13, 2016 787
Figure 3. Fecal Neutral Sterol and Bile Salt Excretion before and after Treatment with Ezetimibe
(A) After stopping ezetimibe treatment at t = 0, fecal neutral sterol (FNS) gradually decreased toward baseline levels (n = 10).
(B) Total FNS production in time under basal and after 4 weeks of ezetimibe treatment (n = 10).
(C) Ezetimibe increases fecal bile salt output (n = 10).
(D) Fecal bile salt output increases linearly in time (n = 10).reasons, we were not able to perform direct measurements of
biliary cholesterol secretion in humans. Since biliary cholesterol
secretion is driven by bile salt secretion, we chose a less invasive
bile salt kinetic approach. Bile salt pool sizes were measured ac-
cording to an established method from our laboratory (Bisschop
et al., 2004; Stellaard et al., 1984) and were similar to those in
other populations (Northfield and Hofmann, 1975). The product
of biliary bile salt secretion and biliary CH:cholate ratio, as
measured using the Enterotest, generated the biliary cholesterol
secretion. Although the method is based on a number of
assumptions, the values for biliary cholesterol secretion in this
study are in line with literature data obtained at the time when
experimental procedures were less bound to ethical constraints
(see Carey andMazer, 1984, for review). We validated our results
from the Enterotest in a separate experiment with five volunteers,
in which CH:cholate ratios measured with the Enterotest were
similar to those in duodenal sampled bile (Figure S1). It therefore
seems reasonable to assume that our estimationof biliary choles-
terol secretion is valid. We would like to stress that even though
we cannot exclude experimental error in the estimation of biliary
cholesterol, in line with results from recent studies (Wang et al.,
2008; Kishikawa et al., 2015), ezetimibe treatment does not in-
crease the biliary bile salt:cholesterol ratio. Hence, increased
biliary cholesterol secretion can by no means explain the in-
creases in FNS induced by ezetimibe.
In summary, we confirm that transintestinal excretion of blood-
derived cholesterol plays a physiological role in humans. The ac-
tivity of this pathway relative to hepatobiliary secretion is lower in
humans than in mice. However, TICE is sensitive to pharmaco-
logical stimulation by ezetimibe, and we found that increased788 Cell Metabolism 24, 783–794, December 13, 2016TICE accounted for most of the cholesterol mobilized by the
drug. Recent specific targeting of intestinal RCT showed pro-
found effects on CVD progression (Lo Sasso et al., 2010) and
macrophage RCT (MiGen Investigators et al., 2014; Temel
et al., 2010; Yasuda et al., 2010). Our findings imply that stimula-
tion of TICE may explain, in part, the large effects seen on CVD
incidence in humans with mutations in the gene encoding
NPC1L1 (MiGen Investigators et al., 2014). Given the fact that
robust stimulation of biliary cholesterol secretion is not possible
in humans due to the high cholesterol saturation index of bile,
stimulation of TICE may serve as an alternative strategy to in-
crease cholesterol disposal and reduce the risk of cardiovascu-
lar events.EXPERIMENTAL PROCEDURES
Humans and Animals
Subjects were recruited via advertisements in local newspapers. Adult males
with plasma LDL-C concentrations between 2.8 and 5.0 mmol/L were consid-
ered eligible as long as they did not meet the following exclusion criteria: use
of medication or plant sterol- or stanol-enriched food products; a history of
arterial disease, including unstable angina, myocardial infarction, transient
ischemic attack, or cerebrovascular accident; gallstone or other biliary dis-
ease; diabetes mellitus; thyroid illness; uncontrolled hypertension; familial
hypercholesterolemia (FH), diagnosed either by genotyping or by WHO diag-
nostic criteria; plasma TG concentrations >3.0 mmol/L; BMI >30 kg/m2; or
excessive alcohol consumption. This study was approved by the Institutional
Review Board of the Academic Medical Center in Amsterdam. Each partici-
pant gave written informed consent.
Male, 12-week-old Abcg8 knockoutmice and their C57BL/6JWT littermates
(Klett et al., 2004) were housed in a light-controlled (12:12) and temperature-
controlled (21C) facility and received laboratory chow (RMH-B, Hope Farms)
Figure 4. Cholesterol Fluxes under Basal and Ezetimibe-Treated Conditions in Humans
(A) Dietary cholesterol intake is depicted.
(B) Biliary cholesterol secretion, calculated as described in the text and Supplemental Experimental Procedures, is depicted.
(C) Fractional cholesterol absorption is depicted.
(D) FNS excretion is depicted.
(E) Bile salt (BS) excretion is depicted.
(F) Total sterol (neutral sterol + bile salt) synthesis is depicted.
(G) Transintestinal cholesterol excretion is depicted.
n = 10; *p < 0.05; **p < 0.01.
Cell Metabolism 24, 783–794, December 13, 2016 789
Figure 5. Cholesterol Fluxes under Basal
and Ezetimibe-Treated Conditions in WT
and Abcg8–/– Mice
(A) Dietary cholesterol intake is depicted.
(B) Biliary cholesterol is depicted.
(C) Fractional cholesterol absorption is depicted.
(D) FNS excretion is depicted.
(E) Bile salt (BS) excretion is depicted.
(F) Total sterol (neutral sterol + bile salt) synthesis is
depicted.
(G) Transintestinal cholesterol excretion is depicted.
n = 8–10; *p < 0.05 ; **p < 0.01.ad libitum. All experiments were approved by the Ethics Committee for Animal
Experiments of the University of Groningen.
Human Subjects
The tracer administration and sampling protocol (Figure 1), based on our
prior study in mice (van der Veen et al., 2009), was modified for applicability
in humans. Participants kept a cholesterol-restricted diet (<300mg/day) from
7 days prior to the dual cholesterol tracer administration (T = 0 hr) until the end
of study (T = 168 hr). During the study period following T = 0 hr, subjects
consumed two supervised meals per day at the research facility and kept a
dietary record while maintaining their usual patterns of smoking and physical
activity. In order to normalize fecal isotope recovery measurements for vari-
ations in fecal flow, subjects ingested tracer capsules containing 3 mg
[5,6,22,23-D4]-sitostanol (Cambridge Isotope Laboratories) three times daily
with their meals from T =48 hr until the end of the study. The day before the
dual cholesterol tracer administration, participants collected one baseline
stool sample (T = 24 hr) using a FSC specimen collection system (Fisher
Scientific). That evening, subjects ingested a bile salt tracer 2 hr after dinner
(T =13 hr). This involved a single oral dose of 50 mg [2,2,4,4-D4]-cholic acid790 Cell Metabolism 24, 783–794, December 13, 2016(D4-CA, Sigma Aldrich, Isotec Inc.) dissolved
in 200 mL 0.5% sodium bicarbonate in water
together with 0.4% dextrose. The cholate tracer
was used to measure bile salt pool size and turn-
over rate, based on measurement of enrichment
in postprandial plasma in the subsequent 4 days
(Stellaard et al., 1984).
The next morning (T = 0 hr), participants were
admitted to the hospital in a fasting state for a
30 min infusion of 50 mg [3,4-13C2] cholesterol
(Isotec) dissolved in 33 mL 10% Liposyn III
(Hospira Inc.). The 13C2-cholesterol tracer solu-
tion was prepared for injection by dissolving
the tracer in warm USP ethanol into a clear so-
lution under sterile conditions. Thereafter, the
isotope and ethanol mixture was added to
10% Liposyn III for a total administrable volume
of 33 mL. Immediately after infusion of the
intravenous tracer dose, subjects ingested
50 mg of [25,26,26,26,27,27,27-D7] cholesterol
(Cambridge Isotope Laboratories), administered
in a stomach-soluble gelatine capsule, together
with a standardized breakfast, as previously
described (Jakulj et al., 2013). Subjects re-
frained from eating for 4 hr following the test
meal to allow complete gastric emptying. Blood
samples were collected directly before the 13C2-
cholesterol infusion and at 4, 9, 11, 23, 25, 28,
30, 48, 72, 120, and 168 hr after administration
of the cholesterol tracers. Plasma was isolated
by centrifugation and stored at 80C for sub-
sequent cholesterol extraction and measure-
ment of the tracer enrichments, as describedbelow. Subjects collected daily fecal samples from T = 0 hr until the end
of study (T = 168 hr). At T = 24 hr, a biliary sample was obtained in the
morning fasting state by use of the Enterotest (HDC Corp). This commer-
cially available device for sampling of gastrointestinal contents was used
to determine biliary bile salt and cholesterol contents, as previously
described (Muraca et al., 1991; Van der Meer et al., 1990). Participants
swallowed the encapsulated nylon thread with water in the evening before
the T = 24 hr study visit; one end was taped at a corner of the mouth. The
capsule dissolves in the stomach, and the thread, weighed at its distal
end, passes into the duodenum. The next morning (T = 23 hr), an intrave-
nous dose of 0.05 mg/kg synthetic cholecystokinin (CCK) (sincalide, Kine-
vac, Bracco Diagnostics) was administered to induce gallbladder contrac-
tion. After 1 hr, the thread, which was colored yellow with bile at the distal
end, was withdrawn and immediately frozen at 80C for subsequent
cholesterol and bile salt extraction and measurement of tracer enrich-
ments. Finally, during a period of 5 hr following the CCK dose, plasma
was obtained at 30 min intervals for measurement of bile salt profiles in
order to estimate bile salt turnover as described in the Supplemental
Experimental Procedures.
Figure 6. Schematic Representation of Cholesterol Transport Pathways through the Enterocyte in WT and Abcg8–/– Mice in Presence and
Absence of Ezetimibe
(A) Representation of WT mice.
(B) Representation of Abcg8/ mice.
Data for the different fluxes (J) were extracted from the experimental data shown in Figure 5. Values for Jabcg5/g8 in WTmice were estimated by subtracting FNS in
Abcg8/ mice from FNS in WT mice. In the steady state, Jchylomicron must be equivalent to the amount of cholesterol absorbed (JNPC1l1). Data for the condition
plus ezetimibe are presented in italics. All data are given as mg/day for 8–10 mice.A second experiment was performed according to the same tracer adminis-
tration and sampling protocol after subjects had used 10mg ezetimibe daily for
a period of 28 days before T = 0.
Mice
To assess fractional cholesterol absorption and cholesterol kinetics, mice
received an intravenous dose of 0.3 mg (0.73 mmol) cholesterol-D5 (Medical
Isotopes, Inc.) dissolved in Intralipid (20%, Fresenius Kabi) and an oral dose
of 0.6 mg (1.535 mmol) cholesterol-D7 (Cambridge Isotope Laboratories,
Inc.) dissolved in medium-chain TG oil (Pharmacy UMCG) 10 days prior to
the end of the experiment. Blood spots were collected from the tail at 0, 3,
6, and 12 hr and subsequently every 24 hr after administration of the stably
labeled cholesterol. At the end of the experiment, mice were anesthetized
by intraperitoneal injection with Hypnorm (1 mL/kg; Janssen Pharmaceuticals)
and Diazepam (10 mg/kg; Actavis). After ligation of the bile duct, the gall-
bladder was cannulated. Bile collected during the initial 5 min after cannulation
was disposed to ensure no gallbladder bile was collected; subsequently, he-
patic bile was collected for 30 min (Kuipers et al., 1996). During the collection
period, body temperature was stabilized in a humidified incubator. After bile
had been collected, mice were sacrificed by cardiac puncture and tissues
were rapidly excised.
Analytical Procedures
Fasted plasma TC, HDL-C, and TG concentrations were measured with stan-
dard automated methods; LDL-C concentrations were calculated using the
Friedewald formula (Friedewald et al., 1972).Plasma cholesterol was extracted with ethanol and acetone (1:1) (Neese
et al., 1993) and derivatized using N,O-bis-(trimethylsilyl)trifluoroacetamide
(1% trimethylchlorosilane) and pyridine (1:1) at room temperature. Bile salts
were deconjugated, extracted from plasma, and derivatized according to
Hulzebos et al. (2001).
Biliary lipids were extracted according to Bligh and Dyer (1959) from the
freshly frozen bile samples and from bile eluted from the Enterotests as previ-
ously described (Muraca et al., 1991). Biliary free cholesterol was derivatized
using N,O-bis-(trimethylsilyl)trifluoroacetamide and pyridine (1:1) with 1% tri-
methylchlorosilane at room temperature.
Daily frozen fecal samples were thawed and homogenized with distilled
water (1:1; w/w). A total of 10 mL of fecal homogenate was dispensed into a
10 mL plastic tube. Bile salts were extracted and quantified as their methyl-
trimethylsilyl derivatives according to Setchell et al. (1983). Bile salts were
analyzed by gas chromatography (Agilent 6890) using a CPSil 19 capillary col-
umn (25 m 3 0.25 mm 3 0.2 mm; Chrompack).
Daily FNS excretion rates were calculated by expressing the results relative
to D4-sitostanol, measured by gas chromatography/mass spectrometry (GC/
MS), as described below. Enrichments of stable isotopes in the FNS were
measured in the cholesterol fraction, whereas total FNS was determined as
the sum of fecal cholesterol and its bacterial metabolites, whichwere assumed
to have similar specific enrichments to cholesterol.
Plasma and biliary bile salt profiles were determined using liquid chromatog-
raphy/mass spectrometry (LC-MS/MS) (Api3000; AB Sciex) coupled to a
Shimadzu HPLC. The system was controlled by Analist 1.6 software (AB
Sciex). The LC conditions were as follows: an XBridge Shield RP18 columnCell Metabolism 24, 783–794, December 13, 2016 791
(3.5 mm, 100 mm3 2.1 mm ID; Waters) was used; the mobile phase consisted
of 20 mM ammoniumacetate ([pH 8]; mobile phase A) and methanol (mobile
phase B) at a total flow rate of 0.2 mL/min. The injection volume of all samples
was 10 mL.
Measurement of Mass Isotopomer Distribution
D7-cholesterol derivatives were analyzed by GC/MS, electron impact (EI)
mode (Agilent 7890A/5975C) using a ZB-5MS capillary column (30 m 3
0.25 mm 3 0.25 mm; Phenomex). Ions with m/z 458-465 generated in the
EI mode corresponding to the m0–m7 mass isotopomers were corrected
for the fractional distribution due to natural abundance of 13C by multiple
linear regression, as described by Lee et al. (1991), in order to obtain
excess fractional distribution of mass isotopomers M0–M7 resulting from
isotope dilution. In this approach, M7 represented the orally administered
label.
Isotopic enrichments of 13C2-cholesterol were measured using gas chroma-
tography combustion-isotope-ratio mass spectrometry (GC-C-IRMS) (Delta
Plus Thermo Electron) using a ZB-5MS capillary column (30 m 3 0.25 mm 3
0.25 mm; Phenomex). Isotopic enrichments determined as atom percent
excess (APE) were converted into molar percent excess (MPE) using a linear
calibration curve.
D4-cholate (D4-CA) was measured on an Agilent 7890A GC connected to
an Agilent 5975C MSD (Agilent). Gas-liquid chromatographic separation was
performed on a 10 m 3 0.100 mm column with a film thickness of 0.1 mm
(DB-5MS; Agilent). Isotope ratios were determined in the selected ion moni-
toring mode on m/z 623.4 (M0) and 627.3 (M4).
D4-sitostanol derivatives were analyzed by GC/MS, EI mode (Agilent 7890A/
5975C) using a ZB-5MS capillary column (30 m 3 0.25 mm 3 0.25 mm;
Phenomex). Ions with m/z 488–493 generated in the electron impact mode
corresponding to the m0–m5 mass isotopomers were corrected for the frac-
tional distribution due to natural abundance, as described by Lee et al.
(1991), in order to obtain excess fractional distribution of mass isotopomers
M0–M5.
Calculation of Kinetic Parameters and Cholesterol Fluxes
The methods to calculate fractional and absolute contributions of the distinct
fluxes to total FNS loss resemble those previously described in mice (van der
Veen et al., 2009). From plasma and fecal decay curves of the intravenously
administered 13C2-cholesterol and orally administered D7-cholesterol tracers,
combinedwith both enrichments in the bile sample, several kinetic parameters
were calculated. This was done by use of a mathematical kinetic model
(SAAM-II software, The Epsilon Group, version 2.3). Combined with measure-
ment of dietary cholesterol intake, fractional cholesterol absorption, excreted
fecal NS and bile salt mass, bile salt pool size, secretion rate, and biliary CH/
BS, specific sources of cholesterol contributing to total FNS mass could be
calculated as described below. A more detailed description of calculations
with justification of equations is provided in the Supplemental Experimental
Procedures.
Dietary Intake, Fractional Cholesterol Absorption, and Cholesterol
Synthesis
Dietary cholesterol intakes were calculated using a freely available Dutch nutri-
tion database program (www.dieetinzicht.nl). Fractional cholesterol absorp-
tion (Fa) was calculated from the area under the curve of intravenously and
orally administered cholesterol isotopes and their dose, as described in the
Supplemental Experimental Procedures.
Cholesterol synthesis was estimated according to the cholesterol balance
method, i.e., as the difference between fecal elimination of cholesterol, both
as BS and FNS, and accurately assessed dietary cholesterol intake (Grundy
and Ahrens, 1969; Samuel and McNamara, 1983).
BBS results from the product of bile salt pool size (QBS) and the fractional
elimination rate of total bile salts from blood (kBS). The latter was estimated
from the plasma decay curves of total bile salt concentrations measured at
30 min intervals during 5 hr following administration of the intravenous dose
of cholecystokinin (Supplemental Experimental Procedures; Figure S3). Sub-
sequently, BBS was multiplied by the biliary CH/BS, yielding the biliary choles-
terol secretion rate.
Statistical Analyses
Differences in measured fluxes between the basal and repeated experiment
after ezetimibe treatment were statistically analyzed by use of paired sample
t tests and, if data were skewed, the Wilcoxon signed rank test (SPSS Inc.,792 Cell Metabolism 24, 783–794, December 13, 2016version 15.0). Values in Figures 4 and 5 are presented as Tukey boxplots.
Significance was tested using the Kruskal-Wallis H test followed by Conover
posthoc comparisons. *p < 0.05, **p < 0.01. Data in the text are presented
as mean ± SE; p < 0.05 was considered statistically significant.
ACCESSION NUMBERS
The accession number for the microarray data is Genome Spatial Events:
GSE77236.
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Kruit, J.K., Plösch, T., Havinga, R., Boverhof, R., Groot, P.H., Groen, A.K., and
Kuipers, F. (2005). Increased fecal neutral sterol loss upon liver X receptor acti-
vation is independent of biliary sterol secretion in mice. Gastroenterology 128,
147–156.
Kuipers, F., van Ree, J.M., Hofker, M.H., Wolters, H., In’t Veld, G., Havinga, R.,
Vonk, R.J., Princen, H.M., and Havekes, L.M. (1996). Altered lipid metabolism
in apolipoprotein E-deficient mice does not affect cholesterol balance across
the liver. Hepatology 24, 241–247.
Lauridsen, B.K., Stender, S., Frikke-Schmidt, R., Nordestgaard, B.G., and
Tybjærg-Hansen, A. (2015). Genetic variation in the cholesterol transporter
NPC1L1, ischaemic vascular disease, and gallstone disease. Eur. Heart J.
36, 1601–1608.
Le May, C., Berger, J.M., Lespine, A., Pillot, B., Prieur, X., Letessier, E.,
Hussain, M.M., Collet, X., Cariou, B., and Costet, P. (2013). Transintestinal
cholesterol excretion is an active metabolic process modulated by PCSK9
and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33, 1484–
1493.
Lee, W.N., Byerley, L.O., Bergner, E.A., and Edmond, J. (1991). Mass
isotopomer analysis: theoretical and practical considerations. Biol. Mass
Spectrom. 20, 451–458.Lin, X., Racette, S.B., Lefevre, M., Ma, L., Spearie, C.A., Steger-May, K., and
Ostlund, R.E., Jr. (2011). Combined effects of ezetimibe and phytosterols on
cholesterol metabolism: a randomized, controlled feeding study in humans.
Circulation 124, 596–601.
Lo Sasso, G., Murzilli, S., Salvatore, L., D’Errico, I., Petruzzelli, M., Conca, P.,
Jiang, Z.Y., Calabresi, L., Parini, P., and Moschetta, A. (2010). Intestinal spe-
cific LXR activation stimulates reverse cholesterol transport and protects
from atherosclerosis. Cell Metab. 12, 187–193.
Masson, C.J., Plat, J., Mensink, R.P., Namiot, A., Kisielewski, W., Namiot, Z.,
F€ullekrug, J., Ehehalt, R., Glatz, J.F., and Pelsers, M.M. (2010). Fatty acid- and
cholesterol transporter protein expression along the human intestinal tract.
PLoS ONE 5, e10380.
Muraca, M., Vilei, M.T., Miconi, L., Petrin, P., Antoniutti, M., and Pedrazzoli, S.
(1991). A simple method for the determination of lipid composition of human
bile. J. Lipid Res. 32, 371–374.
Nakano, T., Inoue, I., Takenaka, Y., Ono, H., Katayama, S., Awata, T., and
Murakoshi, T. (2016). Ezetimibe promotes brush border membrane-to-lumen
cholesterol efflux in the small intestine. PLoS ONE 11, e0152207.
Neese, R.A., Faix, D., Kletke, C., Wu, K., Wang, A.C., Shackleton, C.H., and
Hellerstein, M.K. (1993). Measurement of endogenous synthesis of plasma
cholesterol in rats and humans using MIDA. Am. J. Physiol. 264, E136–
E147.
Northfield, T.C., and Hofmann, A.F. (1975). Biliary lipid output during three
meals and an overnight fast. I. Relationship to bile acid pool size and choles-
terol saturation of bile in gallstone and control subjects. Gut 16, 1–11.
Rosenfeld, R.S., and Hellman, L. (1959). The relation of plasma and biliary
cholesterol to bile acid synthesis in man. J. Clin. Invest. 38, 1334–1338.
Samuel, P., and McNamara, D.J. (1983). Differential absorption of exogenous
and endogenous cholesterol in man. J. Lipid Res. 24, 265–276.
Setchell, K.D., Lawson, A.M., Tanida, N., and Sjövall, J. (1983). General
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